Here are five notes:
1. VIEKIRA XR is an extended-release co-formulation of the active ingredients in VIEKIRA PAK.
2. It is intended to treat patients with chronic genotype 1 hepatitis C virus infection, including those with compensated cirrhosis.
3. The FDA approved VIEKIRA XR based on data from seven Phase III clinical trials that included more than 2,300 patients.
4. VIEKIRA XR is taken orally with meals.
5. AbbVie is a global, research-based biopharmaceutical company founded in 2013.
More articles on GI/endoscopy:
5 most read GI/endoscopy stories: July 18 — 22
Schizophrenic son of gastroenterologist Dr. William Wu found guilty of stabbing him: 5 notes
LifeBond’s surgical sealant kit receives FDA IDE approval: 4 things to know
